The US Food and Drug Administration approved CSPC Pharmaceutical's (HKG:1093) US clinical trials for its JMT108 drug for advanced malignant tumors, according to a Tuesday filing with the Hong Kong bourse.
The product relieves immunosuppression on programmed cell death protein 1 positive tumor infiltrating immune cells, the filing said.
Shares in the drug company fell 4% during Wednesday's morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.